The global pharmaceutical dispensing systems market is foreseen to value over US$ 6 billion by the end of 2026 and growing at a CAGR of over 7% during the forecast period, 2019 to 2026.

Dispensing systems are unique, independently functioning which dispense material into another system for its functioning. They are electronically and mechanically equipped to dispense the specific quantity of substance at the required time. Dispensing systems function on their own and execute the tasks with the help of robotic systems equipped with sensors and high-end tech specifications. The need for accuracy, control and customization in chemical and electronic industries is fulfilled by the implantation of dispensing systems.

There is going to be a huge demand for dispensing systems in the foreseeable future, particularly in the medical diagnostic industry, the major sector to employ numerous dispensing equipment ranging from manual to fully automated. Pharmaceutical is the next leading sector, where dispensing medicine is a daily task. Various other research sectors such as the chemical industry, find dispensing systems to be useful, especially manual type. Any industry which requires accuracy and availability of material then turns to this market and uses either stand-alone dispensers or dispenser modules fitted in machines.  
Increase in the number of hospitals to cater to the huge population aid the growth of this market. Government incentives and aid in making medicine more accessible help advance the market’s product.

Pharmaceutical Dispensing Systems Market: Restraints 
+ Expensive machinery
+ Room for error 

Pharmaceutical Dispensing Systems Market Segmentation
By Product Type

+ Automated Pill Dispenser
+ Manual Pill Dispenser

By End User
+ Hospitals
+ Clinics
+ Outpatient Centre
+ Homecare Settings
The outpatient centre segment is expected to register the fastest growth due to ongoing technological advancement.  Hospitals are presently reigning the end-user segment for pharmacy dispensing machines market. Frequent medication and rampant increase in the number of patients visiting healthcare centres drive the dispensing system in hospitals market growth furthermore.

By Region
+ North America
+ Latin America
Europe
+ Asia Pacific
+ Rest of the World
North America is currently having a major market share and dominating the geographical segment for the global pharmaceutical dispensing machines market. Housing major competitors such as Omnicell, ScriptPro, InstyMeds etc., further consolidate pharmacy dispensing machines market growth in North America.
Europe accounts for significant market share in the global market. The Asia Pacific is expected to grow at a fast pace as well owing to the rising prevalence of chronic disease and lack of skilled workforce to dispense appropriate medicines with accurate dosage.

Competitive Landscape:  
+ Tier 1 players- Established companies in the market with a major market share
+ Tier 2 players
+ Emerging players which are growing rapidly 
+ New Entrants  

The market of Pharmaceutical Dispensing Systems include firms like ScriptPro LLC, McKesson Corporation, Swisslog Holding Ltd., Omnicell, ARxIUM, Care Fusion Corporation, AmerisourceBergen Corporation, and others

FutureWise Key Takeaways 
+ Growth prospects
+ SWOT analysis 
+ Key trends 
+ Key data-points affecting market growth 

Objectives of the Study: 
+ To provide with an exhaustive analysis on the global pharmaceutical dispensing systems market by product type, by end-user, and by region
+ To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
+ To evaluate and forecast micro-markets and the overall market 
+ To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
+ To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
+ Profiling of companies to evaluate their market shares, strategies, financials and core competencies  

 

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com

The global liquid biopsy market is anticipated to value over US$ 8.4 billion by the end of 2026 and expanding at a CAGR of over 20% during the forecast period, 2019 to 2026.  

Cancer is one of the most prevalent diseases owing to which the need for various cancer treatments. Techniques like biopsy are used to understand the tumour nature so that cancer can be managed correctly which can be eliminated eventually. There are two techniques used, one is the conventional method of solid tissue biopsy and other is the newly introduced liquid biopsy technique. Metastatic relapse evaluation and minimal invasiveness are some of the advantages of using liquid biopsy over solid tissue biopsy which would increase its demand resulting in the growth of the market. A further boost to the market growth will be contributed by factors like patient preference to get minimally invasive therapy, increase in the number of cancer cases and increase in the disposable income among patients suffering from cancer. Also, using liquid biopsy tests to identify and treat rare cancers will provide multiple opportunities for key market players to establish and expand their business.  

Insights on Global Liquid Biopsy Market:
By Region

•    North America
•    Europe
•    Asia Pacific
•    Latin America
•    Rest of the World
North America is the major shareholder of the global market as it has a high adoption rate of liquid biopsy test and thus is expected to show a higher market growth rate during the forecast period. Europe follows North America and it is primarily dominated by the UK, France and Germany. The market spaces with the most number of opportunities for manufacturers are the Asia Pacific and Latin America as these markets are yet to explored and penetrated properly. These regions will, therefore, experience a higher market growth rate during the forecast period. Rest of the World possesses a small share of the global market due to limited adoption.

By Circulating Biomarker
•    Circulating tumour DNA
•    Circulating Tumour Cells (CTC)
•    Extracellular Vesicles
•    Others
Circulating tumour DNA is one of the most analysed biomarkers due to its capability of detecting cancer in earlier stages and prediction of cancer recurrence. CT-DNA and a combination of various biomarker analysis have provided sensitivity ranging from 69% to 98% for five different types of cancer according to a study by Cohen et al. These are the reasons that this market segment will receive good traction during the forecast period. Exosomes, which are small vesicles, were thought to be as waste disposal units initially. But recent researches suggest that they play an important role in the initiation of cancer and also in its progression and metastasis. Due to this new revelation, this market segment will get a significant amount of traction during the forecast period and especially in the developed economy market regions like North America and Europe as they adopt newer technologies with ease. 

By End User
•    Hospitals
•    Cancer Research Centres
•    Diagnostic Laboratories
Hospitals dominate this market segment due to the provision of advanced infrastructure and introduction of multi-speciality hospitals. It is expected that they will dominate the global market in the forecast period as well. 

Competitive Landscape:
•    Biocept Inc.
•    Qiagen Corp.
•    Roche Diagnostics
•    RainDance Technologies 
Biocept’s Target Selector liquid biopsy follows all the clinical regulations listed by the National Comprehensive Cancer Network (NCCN) and thus focusses on clinically-actionable cancer biomarkers that will lead to an efficient tumour identification and treatment which will provide them higher traction in the market during the forecast period.  

FutureWise Key Takeaways:
•    Growth prospects
•    SWOT analysis 
•    Key trends 
•    Key data-points affecting market growth 

Objectives of the Study:
•     To provide with an exhaustive analysis on the Global Liquid Biopsy Market by Biomarker Type, by End-User, and by Region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and Rest of the World
•    To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
•    Profiling of companies to evaluate their market shares, strategies, financials and core competencies 

 

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com

Cell Isolation or Cell Separation Market to value over USD 14 billion and register a CAGR of over 16.1% during the forecast period of 2019 to 2026.

The cell isolation market is considered a growing market with a lot of potentials. Due to increasing investments and growing interest from established firms namely the companies in the biotechnology sphere are providing ample opportunities for the market to grow during the forecast period. The increasing initiatives undertaken to promote research activities in cancer and stem cell is also boosting the global market. Advancements in technology have made the market and its services more accessible to the public as well as increased the adoption rate. Improvements such as efficient and better separation of biological molecules including proteins, nucleic acids, chromatin, protein complexes for subsequent analysis. Thus, the demand for these products is mounting, which is expected to support cell isolation market growth during the forecast period.

Augmenting demand for personalized medicine is another major factor propelling the industry growth. The cell separation techniques can be used in personalized medicine for early detection of disease, selection of appropriate treatment, and determining the prognosis of the therapy.

Based on the product, the cell isolation market is segmented into consumables and instruments. The consumables segment is predicted to grow at the highest CAGR. Increasing incentives and investments by companies to expand product portfolios and the federal support for enhancing cell-based research are driving the growth of this segment.

By cell type, the cell isolation market is segmented into human cells and animal cells. The segment of human cells is assumed to account for major market share during the forecast period. To promote research, public and private organizations have made heavy investments. Thus the field of human cells, growing application areas of human stem cells, and the high prevalence and growing incidence of diseases such as cancer, have helped the growth of the market.

On the basis of technique, the cell isolation market is segmented into centrifugation, surface marker, and filtration. The technique of centrifugation is presumed to account the highest market share during the forecasted time frame. This technique is prevalent and employed on a large scale by biotech and biopharmaceutical companies and is economical across all industries.

Based on the application, the cell isolation market is segmented into biomolecule isolation, cancer research, stem cell research, tissue regeneration, in vitro diagnostics and therapeutics.

The biomolecule isolation accounted for major market share during the forecast period.

This is primarily due to increasing investment in biopharmaceutical production and a rise in the use of personalized medicine.

Based on end-users, the cell isolation market is segmented into research laboratories & institutes, hospitals & diagnostic laboratories, biotechnology & biopharmaceutical companies. The biotechnology & biopharmaceutical companies segment is predicted to grow unboundedly and account for the largest share. This dominance is primarily attributed to the widespread adoption of advanced instruments in biotechnology and biopharmaceutical companies for cell-based experiments & cancer research. The increasing number of R&D facilities globally is another driving factor.

North America is expected to dominate the market during the forecast period. The advanced research infrastructure and the presence of established firms have fueled the regional market. Advancements in technology and focus on drug discovery in this region drive sector growth.

The Asia Pacific is predicted to exhibit the highest growth during the forecast period owing to the growing number of clinical research organizations and biopharmaceutical companies in this region. The availability of a vast genome pool, less stringent regulations for drug development, and availability of skilled personnel in this region are some of the major factors responsible for the growth of the sector in this region.

Prominent players in the market include Thermo Fisher Scientific, Inc., Merck KGaA; BD Biosciences, Beckman Coulter, Inc., Terumo BCT, GE Healthcare and STEMCELL Technologies Inc.

Competitive Landscape

?     Miltenyi Biotec launched the MultiMACS X Device which helped the company expand its product portfolio and increase trade

?     Becton, Dickinson , and Company (BD) launched BD FACSymphony which helped them intercept the market more

Global Cell Isolation/Cell Separation Market Segmentation:

By Product

?     Consumables

¦  Reagents, kits, media, and sera

¦  Beads

¦  Disposables

?     Instruments

¦  Centrifuges

¦ Flow cytometers

¦ Filtration systems

¦ Magnetic-activated cell separator systems           

By Cell Type

?       Human cells

?      Animal cells

By Technique

?      Centrifugation                 

?      Surface marker

?      Filtration              

By Application

?       Biomolecule isolation

?       Cancer research

?       Stem cell research

?       Tissue regeneration

?       In vitro diagnostics

?       Therapeutics         

By End-User

?       Research laboratories and institutes

?       Hospitals and diagnostic laboratories

?       Cell banks

?       Biotechnology and biopharmaceutical companies

By Region:

?      Europe

?      North America

?      APAC

?      Latin America

?      Rest of World

Competitive Landscape:

?      Tier 1 players- established companies in the market with a major market share

?      Tier 2 players

?      Emerging players which are growing rapidly

?      New Entrants 

FutureWise Takeaways

?      Growth prospects

?      SWOT analysis

?      Key trends

?      Key data points affecting market growth 

Objectives of the Study:

?     To provide an exhaustive analysis on the global cell isolation/cell separation market by product, by cell type, by application,by technique, by end-user, and by region

?      To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)

?      To evaluate and forecast micro-markets and the overall market

?      To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the rest of the world

?      To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

?     Profiling of companies to evaluate their market shares, strategies, financials and core competencies                

 

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com

The global leadless pacemakers market is forecasted to value over US$ 260 million by the end of 2026 and growing at a CAGR of over 21% during the forecast period, 2019 to 2026.

The pacemakers currently used to treat cardiac patients use lead as a primary material to connect pulse generator to heart chamber. This resulted in problems like lead fracture, breaking of the insulation which would in turn affect the lifecycle of the pacemaker. Due to all these factors, researchers developed the idea of leadless pacemakers. They are transplanted directly in the right ventricle of the heart where the heart muscles receive small electrical impulses from the pacemaker which will result in an acceptable heart rate. In addition to that, leadless pacemakers can be implanted within an hour as they are less invasive as compared to traditional pacemakers. Another advantage of using leadless pacemaker over a traditional pacemaker is that it has a low recovery time which improves its performance. But the most important reason for using leadless pacemakers is because it prevents the heart ventricle from causing any infection which is very critical considering it deals with the heart directly. The market growth for leadless pacemakers is huge as it also has an advantage of reducing the manufacturing cost which will help in penetrating the emerging economy markets during the forecast period.

Insights on Global Leadless Pacemakers Market:
 By Region

•    North America
•    Europe
•    Asia Pacific
•    Latin America
•    Rest of the World
North America dominates the global market as it becomes easy to adopt newer technologies due to the high spending capability of the patient population. The U.S primarily dominates the North American market region as it accounts for more than 90% of the share and is expected to do the same during the forecast period. Europe is the second most dominating market region and countries holding a major share of the market space are UK, Germany, France due to a higher penetration rate, in the end, user market segment. Asia Pacific region is adopting this technology at a faster rate and hence is expected to witness a rise in its market growth during the forecast period. Japan, China and India primarily dominate the Asia Pacific market and is expected to do the same during the forecast period. Latin America is also a fast-growing market with Brazil and Mexico leading the regional market. Rest of the World holds a small share of the global market and is expected to stay the same during the forecast period due to low adoption of the technology.

By Product Type
•    Micra transcatheter system
•    Nanostim
•    Wise CRT
Micra transcatheter pacing system currently leads the global market in this segment. No device dislodgement, an extended battery life, minimal complications post implantation and ease in retrieval are some of the advantages due to which it leads the market and it is expected to do the same during the forecast period. It has been implanted in more than 6000 patients across 30 countries since it was approved by the FDA in April 2016. Nanostim received approval from EMA in 2013 but due to obstacles like an early battery failure and spontaneous docking button detachment resulted in recalling the product which hampered its market position severely. It is thus expected to gain an average market growth rate during the forecast period. 

By End User
•    Hospitals
•    Catheterization Laboratories
Hospitals are a major shareholder in this market segment across the world. Adoption of advanced and updated technologies combined with a superior infrastructure gains them a lot of tractions especially in developed economy markets and it is expected to do the same during the forecast period. 

 Competitive Landscape:
•    Abbott Laboratories
•    Medtronic
Medtronic and Abbott are the only companies who have developed single-chamber leadless pacemakers, therefore, dominating the global market and it is expected that they will dominate the market during the forecast period as well. Abbott has acquired St. Jude Medical who are developing a dual-channel leadless pacemaker and would be the first company in the world to do so if it succeeds.

FutureWise Key Takeaways:
•    Growth prospects
•    SWOT analysis 
•    Key trends 
•    Key data-points affecting market growth 

Objectives of the Study:
•    To provide with an exhaustive analysis on the global Leadless pacemaker market by region, by product type, by end-user
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and Rest of the World
•    To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
•    Profiling of companies to evaluate their market shares, strategies, financials and core competencies 

 

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com

Global Cell Based Assay Market is estimated to value over USD 17.8 billion by 2026 end and register a CAGR of over 7% during the forecast period 2019 to 2026.

The Global Cell Based Assay Market is primarily driven by an increase in funding assigned for research and development, growing preference for cell-based assays and an increase in the drug discovery activities. Furthermore, the adoption of high-output screening methods boosts the cell based assays market growth.

Nonetheless, high instrument costs and restrictions on the usage of reagents are factors that can significantly impede market growth. Furthermore, a lack of skilled labour can restrict the cell based assays market growth.

The inception of innovative technologies like 3D cell-based assays, growing requirement for toxicity screening, advanced detection technologies and broadened cell-based assay applications are projected to provide new opportunities for the expansion of cell based assays market size globally.

Consumable Segment is Predicted to Stimulate the Market Growth Over the Forecast Period

The consumable segment holds the majority of market share in 2019 and is projected to thrive with the highest CAGR value over the forecast period. This growth can be credited to the growing drug discovery activities, especially in emerging economies.

The drug discovery segment is predicted to boost market growth over the forecast period. This growth is due to the increase in investments on research and development by pharmaceutical companies. Furthermore, the increasing prevalence of diabetes and cardiovascular diseases is spurring market growth. Moreover, a rapid rise in the drugs used for treating chronic diseases across the world has boosted the cell based assays market growth.

North America currently dominates the market. However, the Asia Pacific region is predicted to grow at a high CAGR value over the forecast period. The growth in this region is largely due to advancements in infrastructure development and massive investments in research and development by governments of emerging economies.

Key market players include Thermo Fisher Scientific Inc., Danaher Corp., Becton, Dickinson and Company, GE Healthcare, Merck KGaA, Lonza Group Ltd., Perkinelmer Inc., Charles River Laboratories Inc., Cell Signalling Technology Inc., Promega Corp., Cisbio and Cell Biolabs Inc.

Thermo Fisher’s BacMam-enabled Cellular Assays technology is used for mammalian cell line transduction which includes stem cells and primary cells. It is an efficient and robust method for investigating specific signal transduction events with a customised cell background. Thermo Fisher acquired approximately 57% of its total revenue from China and the US combined. The company invests around 4% if its total revenue in research and development to lead the competition in this market.

Danaher, in 2019, announced ClearLLAb 10C System for flow cytometry labs. It includes the initial 10-colour CE-IVD immunophenotyping reagent panels for myeloid as well as lymphoid lineages. These tubes use the DURA innovations dry reagents technology for panels that require no refrigeration.

Global Cell Based Assay Market Segmentation:

By Product & Services

·     Consumables

·     Reagents

·     Assay Kits

o  Reporter Gene Assays

o  Second Messenger Assays

o  Cell Growth Assays

o  Cell Death Assays

o  Other Assay Kits

·     Probes & Labels

·     Microplates

·     Cell Lines

o  Immortalized Cell Lines

o  Primary Cell Lines

o  Stem Cell Lines

·     Instruments

·     Services

By Application

·     Drug Discovery

·     Toxicity Studies

o  Pharmacokinetic Studies

o  Pharmacodynamic Studies

·     Basic Research

·     Other Applications

By End User

·     Pharmaceutical & Biotechnology Companies

·     Academic & Government Institutes

·     Contract Research Organizations

By Region

·     North America

·     Europe

·     Asia Pacific

·     Rest of the World

FutureWise Key Takeaways:

 •   Growth prospects

•   SWOT analysis

•   Key trends

•   Key data-points affecting market growth

Competitive Landscape:

·     Tier 1 players- established companies in the market with a major market share 

·     Tier 2 players 

·     Emerging players which are growing rapidly 

·     New Entrants

Objectives of the Study:

·     To provide with an exhaustive analysis on the cell-based assay market by product & services, by application, by end user and by region

·     To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)

·     To evaluate and forecast micro-markets and the overall market

·     To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe and the rest of the world

·     To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

·     Profiling of companies to evaluate their market shares, strategies, financials and core competencies

 

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com

Global Nurse Call Systems Market is estimated to value over USD 2.3 billion by 2026 end and register a CAGR of over 9% during the forecast period 2019 to 2026.

The global nurse call systems market is steered by advancements in technology and a wide range of nurse call system applications. A rising number of aided living centres and the growing prevalence of Alzheimer’s disease are projected to offer numerous lucrative opportunities for key market players to proliferate in the market.  

Wired Communications Technology is Leading the Global Market

Wired communications are predicted to hold the largest global nurse call systems market share. The advantage offered by this technology, for instance, more security and reliability in connections, which when compared to wireless communications whose connection is hampered due to random signal loss and interference, are steering the market growth. Although, with expeditious advancements in wireless communications, the insistence for wireless nurse call systems is anticipated to grow with a high CAGR over the forecast period.

The buttons segment held the largest global nurse call systems market share. This high share can be credited to the ease of use, faster response time, high reliability and low cost.

The alarms and communications segment is projected to dominate the market over the forecast period. This can be credited to their implementation in critical care settings that are used in hospitals. Moreover, their substantial role in communication streamlining between patient, nurses and other caregivers, which shall further increase the safety of patients and also patient satisfaction. All these factors are expected to inflate the global nurse call systems market size.

The hospital segment is anticipated to subjugate the market. The large market share possessed by this segment can be credited to factors, for instance, improvements in the quality of care, optimizing the safety of patients, increased caregiver productivity, enhancements in the overall satisfaction of patients and streamlining communication between clinicians and patients.

The North America region dominated the global market. This dominance is primarily due to the growing demand and awareness regarding nurse call systems, stringent government norms, improvements in the healthcare infrastructure and the prevalence of key manufacturers in North America.

 

Key market players included in the global nurse call systems industry are Rauland-Borg Corp., Hill-Rom Holdings Inc., Ascom Holding AG, Johnson Controls International PLC, Siemens AG, Ackermann, Jeron Electronic Systems Inc., Azure Healthcare Ltd., Schrack Seconet AG., Intercall Systems Inc.

 

Prominent players like Ascom Holding AG, and Hill-Rom and Rauland-Borg Corporation have a wide range of product portfolios. These firms have created nurse call systems, for instance, Ascom’s Telligence, Navicare by Hill-Rom, and Responder by Rauland-Borg Corp., which have a dominating market presence. Along with strategic partnerships and global distribution network, these market players will have a major market share over the forecast period.

 

Global Nurse Call Systems Market Segmentation:

By Type

  • Button-Based Systems
  • Integrated Communication Systems
  • Mobile Systems
  • Intercom Systems

By Technology

  • Wired Communication
  • Wireless Communication

By Application

  • Alarms & Communications
  • Workflow Optimization
  • Wanderer Control
  • Fall Detection & Prevention

By End User

  • Hospitals and Ambulatory Surgery Centres
  • Long-Term Care Facilities
  • Clinics and Physician Offices

By Region

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

FutureWise Key Takeaways:

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

 

Objectives of the Study:

  • To provide with an exhaustive analysis on the global nurse call systems market by type, by technology, by application, by end user and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
  • To forecast and evaluate micro-markets and the overall market 
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and the rest of the world
  • To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers

 

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com